Skip to main content
SpringerLink
Log in

Pharmacogenomics in Oncology: Current Challenges and Future Strategies

  • Reference work entry
  • First Online:
Handbook of Oncobiology: From Basic to Clinical Sciences

  • 100 Accesses

Abstract

Cancer is a severe genetic disease characterized by uncontrolled growth of cells that is known to be tumor in the body. Benign and malignant are the types of tumors which are noncancerous and cancerous in nature, respectively. Genetic alteration occurred mainly in proto-oncogene, tumor suppressor gene, and DNA repair gene. These all regulate the cell survival and death, mutation in between these gene changes the cell fate and differentiating potency that leads to cancer. Several therapeutic interventions are available for the treatment of the various types of cancer in various stages of cell growth. Currently, therapeutic techniques like oncolytic virus therapy, gene therapy, and immunotherapy are available in the market for treatment of cancer via replacement and modulation in host faulty DNA. These new therapies genetically engineered are highly efficacious and have less side effects than previous one. In a future perspective for invention of new cancer treatment via determination with help of software rather than the use of animals, stem cell and germ cell therapy are renowned therapeutic approaches to treat and cure the cancer through replacement of cancerous cell with normal in vitro prepared cells. In this chapter, we summarize the specific primary genes that are responsible to cause specific cancer, afterward current therapies involve to treat cancer with the interaction with several cancer-associated DNA. In last, we discussed future outcomes related to cancer therapy that could be beneficial to the mankind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

ATM:

Ataxia-telangiectasia mutated

BRCA1:

Breast cancer type 1

CHEK:

Checkpoint kinases

CSF:

Cerebrospinal fluid

DNA:

Deoxyribonucleic acid

DOPC:

1,2-Dioleoyl-sn-Glycero-3-Phosphocholine

DOPE:

1,2-Dioleoyl-sn-glycero-phosphoethanolamine

HSP:

Heat shock protein

LOH:

Loss of heterozygosity

MDC1:

Mediator of DNA damage checkpoint 1

RNA:

Ribonucleic acid

TSG:

Tumor suppressor gene

References

  • Akbulut H, Ocal M, Sonugur G (2015) Cancer gene therapy [Internet]. Gene therapy – principles and challenges. InTech. Available from: https://doi.org/10.5772/61775

  • Belete TM (2021) The current status of gene therapy for the treatment of cancer. Biol Targets Ther 18:67–77

    Google Scholar 

  • Bertwistle D, Swift S, Marston NJ, Jackson LE, Crossland S, Crompton MR, Marshall CJ, Ashworth A (1997) Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res 57:5485–5488

    CAS  PubMed  Google Scholar 

  • Castillo SD, Sanchez-Cespedes M (2012) The SOX family of genes in cancer development: biological relevance and opportunities for therapy. Expert Opin Ther Targets 16:903–919

    Article  CAS  PubMed  Google Scholar 

  • Chaurasia V, Pal S, Tiwari B (2018) Prediction of benign and malignant breast cancer using data mining techniques. J Algorithms Comput Technol 12:119–126

    Article  Google Scholar 

  • Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB (2015) Gene therapies for cancer: strategies, challenges and successes. J Cell Physiol 230:259–271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eisenberg DT (2019) Paternal age at conception effects on offspring telomere length across species – what explains the variability? PLoS Genet 15:e1007946

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Esfahani K, Roudaia L, Buhlaiga NA, Del Rincon S, Papneja N, Miller W (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27:87–97

    Article  Google Scholar 

  • Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244–258

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14:642–662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li L, Liu S, Han D, Tang B, Ma J (2020) Delivery and biosafety of oncolytic virotherapy. Front Oncol 10:475

    Article  PubMed  PubMed Central  Google Scholar 

  • Mehrgou A, Akouchekian M (2016) The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med J Islam Repub Iran 30:369

    PubMed  PubMed Central  Google Scholar 

  • Platzer M, Rotman G, Bauer D, Uziel T, Savitsky K, Bar-Shira A, Gilad S, Shiloh Y, Rosenthal A (1997) Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic DNA containing the entire ATM gene. Genome Res 7:592–605

    Article  CAS  PubMed  Google Scholar 

  • Russell SJ, Peng K-W, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30:658–670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vrooman OP, Witjes JA (2008) Urinary markers in bladder cancer. Eur Urol 53:909–916

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India

    Ayansh Kaushik, Sudhanshu Mallan, Shivani Chib & Kanupriya Chauhan

  2. Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India

    Shamsher Singh

Authors
  1. Ayansh Kaushik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sudhanshu Mallan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shivani Chib
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kanupriya Chauhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shamsher Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shamsher Singh .

Editor information

Editors and Affiliations

  1. Dept. Biotechnology, Panjab University, Chandigarh, Chandigarh, India

    R. C. Sobti

  2. NCR Biotech Science Cluster, Translational Health Sci & Tech Inst, Faridabad, Haryana, India

    Nirmal K. Ganguly

  3. Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India

    Rakesh Kumar

Section Editor information

  1. University Institute of Pharmaceutical Sciences (UIPS), UGC Center for Advanced Study, Panjab University, Chandigarh, Panjab, India

    Anil Kumar

  2. Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, India

    Deepak Kumar

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Singapore Pte Ltd.

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Kaushik, A., Mallan, S., Chib, S., Chauhan, K., Singh, S. (2024). Pharmacogenomics in Oncology: Current Challenges and Future Strategies. In: Sobti, R.C., Ganguly, N.K., Kumar, R. (eds) Handbook of Oncobiology: From Basic to Clinical Sciences. Springer, Singapore. https://doi.org/10.1007/978-981-99-6263-1_54

Download citation

Publish with us

Policies and ethics

Search

Navigation